These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 31859348)

  • 1. Overview of the relevance of PI3K pathway in HR-positive breast cancer.
    Vasan N; Toska E; Scaltriti M
    Ann Oncol; 2019 Dec; 30(Suppl_10):x3-x11. PubMed ID: 31859348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
    Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
    Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
    Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing postmenopausal women with hormone receptor-positive advanced breast cancer who progress on endocrine therapies with inhibitors of the PI3K pathway.
    Brufsky AM
    Breast J; 2014; 20(4):347-57. PubMed ID: 24861776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.
    Yang W; Hosford SR; Dillon LM; Shee K; Liu SC; Bean JR; Salphati L; Pang J; Zhang X; Nannini MA; Demidenko E; Bates D; Lewis LD; Marotti JD; Eastman AR; Miller TW
    Clin Cancer Res; 2016 May; 22(9):2250-60. PubMed ID: 26733612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of PI3K inhibitors in advanced breast cancer.
    Verret B; Cortes J; Bachelot T; Andre F; Arnedos M
    Ann Oncol; 2019 Dec; 30(Suppl_10):x12-x20. PubMed ID: 31859349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer.
    Nunnery SE; Mayer IA
    Drugs; 2020 Nov; 80(16):1685-1697. PubMed ID: 32894420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
    Ciruelos Gil EM
    Cancer Treat Rev; 2014 Aug; 40(7):862-71. PubMed ID: 24774538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
    Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
    Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors.
    Brandão M; Caparica R; Eiger D; de Azambuja E
    Ann Oncol; 2019 Dec; 30(Suppl_10):x27-x42. PubMed ID: 31859350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
    Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
    Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to endocrine therapy in HR + and/or HER2 + breast cancer: the most promising predictive biomarkers.
    Miranda F; Prazeres H; Mendes F; Martins D; Schmitt F
    Mol Biol Rep; 2022 Jan; 49(1):717-733. PubMed ID: 34739691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.
    Miller TW; Balko JM; Arteaga CL
    J Clin Oncol; 2011 Nov; 29(33):4452-61. PubMed ID: 22010023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.
    Miller TW; Hennessy BT; González-Angulo AM; Fox EM; Mills GB; Chen H; Higham C; García-Echeverría C; Shyr Y; Arteaga CL
    J Clin Invest; 2010 Jul; 120(7):2406-13. PubMed ID: 20530877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of resistance to estrogen receptor modulators in ER+/HER2- advanced breast cancer.
    Zhang J; Wang Q; Wang Q; Cao J; Sun J; Zhu Z
    Cell Mol Life Sci; 2020 Feb; 77(4):559-572. PubMed ID: 31471681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
    O'Brien NA; McDermott MSJ; Conklin D; Luo T; Ayala R; Salgar S; Chau K; DiTomaso E; Babbar N; Su F; Gaither A; Hurvitz SA; Linnartz R; Rose K; Hirawat S; Slamon DJ
    Breast Cancer Res; 2020 Aug; 22(1):89. PubMed ID: 32795346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations.
    Schwartzberg LS; Vidal GA
    Clin Breast Cancer; 2020 Aug; 20(4):e439-e449. PubMed ID: 32278641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obesity enhances nongenomic estrogen receptor crosstalk with the PI3K/Akt and MAPK pathways to promote in vitro measures of breast cancer progression.
    Bowers LW; Cavazos DA; Maximo IX; Brenner AJ; Hursting SD; deGraffenried LA
    Breast Cancer Res; 2013; 15(4):R59. PubMed ID: 23880059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.
    Bosch A; Li Z; Bergamaschi A; Ellis H; Toska E; Prat A; Tao JJ; Spratt DE; Viola-Villegas NT; Castel P; Minuesa G; Morse N; Rodón J; Ibrahim Y; Cortes J; Perez-Garcia J; Galvan P; Grueso J; Guzman M; Katzenellenbogen JA; Kharas M; Lewis JS; Dickler M; Serra V; Rosen N; Chandarlapaty S; Scaltriti M; Baselga J
    Sci Transl Med; 2015 Apr; 7(283):283ra51. PubMed ID: 25877889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.
    Bieniasz M; Radhakrishnan P; Faham N; De La O JP; Welm AL
    Clin Cancer Res; 2015 Dec; 21(24):5588-600. PubMed ID: 26289070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.